Navigation Links
Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
Date:5/6/2010

VIENNA, May 6 /PRNewswire-FirstCall/ -- Intercell AG (VSE: ICLL) today announced that it has signed an agreement with Cytos Biotechnology Ltd. to acquire Cytos' platform technology for monoclonal antibody discovery. The technology is based on expression cloning of monoclonal antibodies from human B-cells and enables the identification of anti-infective antibodies to prevent and treat infectious diseases.

Under the agreed terms Intercell will pay EUR 15 million to Cytos. Intercell will own certain unpartnered monoclonal antibody assets, including promising pre-clinical anti-infective antibody candidates discovered by Cytos. The key scientists, who have very successfully developed the technology at Cytos, will be employed by Intercell. The antibody technology complements Intercell's technology platforms and opens novel medically and commercially relevant applications for Intercell's Antigen Identification Program (AIP®). The AIP® has delivered promising vaccine candidates against Staphylococcus aureus (Phase II/III) and Pneumococcus (Phase I) infections, among others, and has also been the basis for partnerships in the antibody field with Merck & Co. and Kyowa Hakko Kirin in these indications, respectively.

In its future antibody discovery activities Intercell will focus on medically and commercially attractive AIP® derived disease targets including Group B Streptococcus and bacteria involved in hospital acquired infections.

"Cytos' outstanding antibody technology complements our innovative R&D technology platform and enables pipeline progression within our existing portfolio," stated Gerd Zettlmeissl, Chief Executive Officer of Intercell.

Wolfgang Renner, CEO of Cytos, commented
'/>"/>

SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
2. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
3. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
4. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
5. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
6. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
7. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
8. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
9. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
10. U.S. Preventive Medicine Acquires Specialty Disease Management
11. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  ANI Pharmaceuticals, Inc. ... Company plans to release its second quarter and year-to-date ... the opening of the U.S. financial markets. The earnings ... section of the Company,s website, www.anipharmaceuticals.com . ... Executive Officer, and Charlotte C. Arnold , Vice ...
(Date:7/28/2014)... , July 28, 2014 PDL BioPharma, Inc. (PDL) ... will release its second quarter 2014 financial results for the ... after market close. PDL,s management will host a conference call ... discuss the financial results.  A slide presentation relating to the ... PDL website. Conference Call Details To access ...
(Date:7/28/2014)...  ProteinSimple announced today that it has launched a ... allows users to detect all proteins separated in the ... can analyze proteins without the need for an antibody.  ... analysis as we know it today. First, the Simple Western ... messy gels, no transfer tanks, no blots, no imaging ...
Breaking Medicine Technology:ANI Pharmaceuticals Schedules Conference Call for Second Quarter 2014 Financial Results 2PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2ProteinSimple Says "Never Run a Gel Again!" 2
(Date:7/28/2014)... University School of Medicine (BUSM) report variants in a ... developing Alzheimer,s disease (AD). The discovery of this novel ... that target PLXNA4 specifically. These findings appear in the ... most frequent age-related dementia affecting 5.4 million Americans including ... more than 40 percent of people age 85 and ...
(Date:7/28/2014)... The Wireline Services Market in Europe report defines and ... forecast of revenue. The Wireline services market in Europe is ... $2.4 billion by 2019, at a CAGR of 11.2%, for ... Wireline Services Market in Europe report, to get an idea ... of the segmentation in the European Wireline Services market, and ...
(Date:7/28/2014)... 28, 2014 (HealthDay News) -- A common inflammatory ... older people may increase the risk for heart ... A British study found that patients with polymyalgia ... -- conditions that affect the blood vessels. Doctors ... patients with polymyalgia rheumatica to reduce their risk ...
(Date:7/28/2014)... July 28, 2014A two-step decision tree analysis, incorporating ... and distill the many available quality standards, guidelines, ... national and international quality standards for radiation therapy, ... 2014 issue of Practical Radiation Oncology ... American Society for Radiation Oncology (ASTRO). , Guidelines, ...
(Date:7/28/2014)... Mediaplanet announced distribution of its third ... campaign that aims to raise awareness about the benefits ... TEALUX , a premium loose leaf tea shop ... readers with educational insight about the accessibility and growth ... forward and make conscious organic choices an option for ...
Breaking Medicine News(10 mins):Health News:Researchers identify potential biomarker for AD 2Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:Inflammatory Muscle Disorder May Raise Risk for Heart Attack, Stroke 2Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 2Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 3Health News:Mediaplanet's "Organic Living" Campaign Raises Awareness About What Nature Invented, With the Help of Partner TEALUX 2
... Systems on the Role of Information Technology in Improving HealthcarePLANO, Texas, April 30 ... executive vice president and chief, ... Dr. Nathaniel Hupert, Director of The Preparedness Modeling Unit, ... Control and Prevention (CDC) and, ...
... their homes is the focus of Penn State,s portion ... that will also test the efficacy of a workplace ... "We,re seeing that stress in the workplace can create ... quality of life in families," says David Almeida, professor ...
... Practice LeaderNEW YORK, April 30 RSM McGladrey, ... a major expansion in the visibility of the ... York office. The expansion will be led by ... in the EBP sector.(Logo: http://www.newscom.com/cgi-bin/prnh/20080305/AQW023LOGO )"Companies ...
... Leaders and National Organizations Respond to Increasing Support ... DebateWASHINGTON, April 30 Men,s Health Network applauds ... today for introducing H.R. 2115, the "Men and ... would establish an Office of Men,s Health within ...
... the Newest Innovation in the Anthelios Franchise for UVA ... April 30 La Roche-Posay, the company that brought ... proudly announces the availability of Anthelios 60 Sunscreen(1) beginning ... brand,s new revolutionary sunscreen range offers ...
... WA April 30, 2009 Biogen Idec (NASDAQ: ... High-Risk AVONEX (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study ... to CHAMPS (Controlled High Risk Subjects AVONEX MS Prevention ... granted approval for use in patients who experienced their ...
Cached Medicine News:Health News:Looking Forward: The Use of Health IT in Crisis 2Health News:Looking Forward: The Use of Health IT in Crisis 3Health News:Looking Forward: The Use of Health IT in Crisis 4Health News:Penn State plays integral role in $35 million stress project 2Health News:RSM McGladrey and McGladrey & Pullen LLP Announce Major Expansion of Employee Benefits Plan Practice in New York 2Health News:RSM McGladrey and McGladrey & Pullen LLP Announce Major Expansion of Employee Benefits Plan Practice in New York 3Health News:U.S. Representatives Hill and Murphy Introduce the 'Men and Families Health Care Act of 2009' 2Health News:Photos: ANTHELIOS 60 Sunscreen(1) with CELL-OX SHIELD(TM) Available May 1 Nationwide 2Health News:Photos: ANTHELIOS 60 Sunscreen(1) with CELL-OX SHIELD(TM) Available May 1 Nationwide 3Health News:First ten-year follow-up shows that treatment with AVONEX leads to long-term benefits in early multiple sclerosis patients 2
Triad Plus PVP-I Scrub Winged Sponges...
Prevail is a fast-acting, effective antimicrobial gel that makes preoperative preps easier. This unique gel formulation comes in a specifically designed, easy to use applicator for excellent flow con...
The applicator is designed for a smooth delivery of the solution for surgical procedures....
... Performance Panel consists of plasma specimens with ... for antibodies to the Hepatitis C Virus. ... manufacturers and diagnostic laboratories to evaluate their ... test systems are included for comparative analysis ...
Medicine Products: